Research News

Intranasal Ketamine Treatment Shows Promise for Uncontrolled Cancer Pain: Presented at AAPM

3.3 from 3 votes
Wednesday, March 13, 2019

DENVER -- March 12, 2019 -- Intranasal ketamine produces favourable results in the treatment of patients with cancer-related pain, according to a small, ongoing, prospective study presented at the 35th Annual Meeting of the American Academy of Pain Medicine (AAPM).

More than half of patients with cancer experience pain, and opioid analgesics are limited by undesirable side effects at higher doses.

“Knowing that intravenous ketamine has analgaesic effects, I wanted to come up with a way to give it easily and frequently for this already fragile patient population,” explained Vinita Singh, MD, Emory University School of Medicine, Atlanta, Georgia.

For the study, the researchers continue to assess pain scores and side effects in 12 patients who have cancer, a numerical pain rating scale (NPRS) score of ≥6, and were taking ≥50 mg morphine equivalents daily prior to the start of the study.

Each patient in the study is required to attend 4 sessions and receive 4 escalating doses of ketamine (10 mg nasal, 10 mg intravenous, 30 mg nasal, and 50 mg nasal). Patients are monitored for 4 hours after treatment.

A total of 7 patients have completed the study. All 3 doses of intranasal ketamine, as well as 10 mg intravenous ketamine, have produced significant reductions in NPRS pain scores.

Intranasal administration of ketamine produces a rapid onset of effects -- within 1 hour of administration.

The researchers analysed time to maximal pain relief, duration of maximal pain relief, and duration of any pain relief, but there were no significant differences in these measures among any of the ketamine treatments.

Emory University School of Medicine

100 Woodruff Circle
Atlanta, GA  30322 USA
(404) 727-6123
Source: firstwordpharma
3.3 from 3 votes
Free Newsletter